Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolynovoCALZF 74 Forward PE Ratio is 28.18 as of Jul. 17, 2026. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.23 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 392 Medical Devices & Instruments companies, Polynovo ranks worse than 76.79% on this metric.
Polynovo (OTCPK:CALZF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Polynovo Forward PE Ratio Related Terms
Polynovo Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Polynovo's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo Forward PE Ratio Chart
Polynovo Annual Data
Trend
2021-06
2024-06
2025-06
Forward PE Ratio
94.34
166.67
53.71
Polynovo Semi-Annual Data
2020-12
2021-06
2021-12
2024-06
2024-12
2025-06
2025-12
Forward PE Ratio
909.09
94.34
181.82
166.67
202.22
53.71
53.23
CALZF vs ABT, SYK, MDT: Forward PE Ratio Comparison
For the Medical Devices subindustry, Polynovo's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Polynovo's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Polynovo (CALZF) has a Forward PE Ratio of 28.18 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #301 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 76.8%.
Is Polynovo's Forward PE Ratio too high?
Polynovo's current Forward PE Ratio is 28.18. The Medical Devices & Instruments industry median Forward PE Ratio is 19.19. Polynovo's value of 28.18 is 46.8% above this industry median. Based on the distribution chart, Polynovo ranks #301 out of 392 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #301 out of 392 companies for Forward PE Ratio. This places Polynovo in the lower half of its industry. The industry median Forward PE Ratio is 19.19. Polynovo's value of 28.18 is 46.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.19, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current Forward PE Ratio of 28.18 is 46.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current Forward PE Ratio is 28.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.23, compared to a current price of $0.62 — trading 72.2% below its estimated fair value. The current Forward PE Ratio is 28.18 and 46.8% above the Medical Devices & Instruments industry median of 19.19. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Polynovo (CALZF), the current Forward PE Ratio is 28.18 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.62 is trading 72.2% below its estimated GF Value™ of $2.23.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
Forward PE Ratio: 28.18
GF Value™: $2.23 vs. price of $0.62 (72.2% below fair value)
Industry Position: 46.8% above the Medical Devices & Instruments median (#301 of 392)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
